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Objectives: This multicentre, parallel group, double-blind, double-dummy, rando-
mised 24-week study was designed to compare the efficacy of salmeterol/fluticasone
propionate combination (SFC) 50/250 mg one inhalation twice daily (bid) with
formoterol/budesonide combination (FBC) 6/200 mg two inhalations bid in patients
with persistent asthma, currently receiving 1000–2000mg/day of inhaled corticos-
teroids.
Methods: The intent-to-treat population comprised 694 patients in the SFC group
and 697 patients in the FBC group.
Results: The primary endpoint, mean rate of all exacerbations over 24 weeks, was
similar in both treatment groups (SFC: 2.69; FBC: 2.79; SFC/FBC ratio 0.96; 95% CL
0.84, 1.10; P ¼ 0:571). A reduction in the rate of exacerbations over time was
observed in both treatment groups. Overall, there was a 30% lower annual rate of
moderate/severe exacerbations in the SFC group compared with the FBC group (95%
CI 0–49%, 52% reduction vs. 1% increase; P ¼ 0:059). This effect increased with time:
in weeks 17–24 the moderate/severe exacerbation rate was 57% lower in the SFC
group compared with the FBC group (95% CI 21–77% reduction; P ¼ 0:006). Similar
improvements in lung function, asthma symptoms and rescue medication usage were
seen with both treatments and both were well tolerated.
Conclusions: Twice-daily treatment with SFC and FBC over 6 months significantly
improved asthma symptoms and lung function in patients with persistent asthma.
The rate of exacerbations was significantly reduced over time on both treatmentsElsevier Ltd. All rights reserved.
49 20 85; fax: +45 89 49 21 10.
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Primary results of the EXCEL study 1153but SFC was found to be significantly superior to FBC in reducing the rate of
moderate/severe exacerbations with sustained treatment.
& 2006 Elsevier Ltd. All rights reserved.Introduction
It is now well recognised that adding a long-acting
b2-agonist (LABA) to inhaled corticosteroid (ICS)
therapy is more effective than ICS alone, even at
double the dose, in improving asthma control in
symptomatic asthmatic patients.1–4 The co-pre-
scribing of an ICS and a LABA is now an integral
part of asthma treatment guidelines.5,6
Combination products, containing both an ICS and
a LABA in one inhaler, have been available for a few
years and may help to improve patient acceptability
and compliance in taking both therapies. The
salmeterol/fluticasone propionate combination
(SFC) Seretides/Advairs/Vianis (GlaxoSmithKline,
Middlesex, UK), contains the LABA salmeterol
xinafoate 50mg and the ICS fluticasone propionate
(FP) at one of three doses, 100mg, 250mg or 500mg,
in a single Diskus/Accuhalers (GlaxoSmithKline,
Middlesex, UK). The formoterol/budesonide combi-
nation (FBC) Symbicorts (AstraZeneca, UK), con-
tains the LABA formoterol 6mg and the ICS
budesonide at one of two doses, 100mg or 200mg,
in a single Turbuhalers (AstraZeneca, UK).
Studies have shown that, compared with FP
alone, SFC is more effective7,8 and compared with
FP and salmeterol given concurrently in separate
inhalers, SFC is at least as effective and well
tolerated.9,10 The Formoterol And Corticosteroids
Establishing Therapy (FACET) study showed that
formoterol and budesonide given concurrently
were more effective than budesonide alone.11 A
comparison of SFC 50/250 mg twice daily (bid)
versus formoterol 12 mg bid and budesonide 800 mg
bid given concurrently showed that SFC was at least
as effective as formoterol and budesonide in
improving morning peak expiratory flow (PEF),
and more effective in reducing exacerbations and
symptoms at night.12
There are very few studies that have compared
the efficacy of the two combination products SFC
and FBC directly. The primary aim of the current
study was to compare the efficacy of SFC delivered
via Diskus/Accuhaler 50/250 mg one inhalation bid
with FBC delivered via Turbuhaler 6/200 mg two
inhalations bid in reducing the rate of exacerba-
tions over a 6-month study period in patients with
persistent asthma. The doses of SFC and FBC chosen
are those recommended in this patient population.Methods
Study design
This was a randomised, double-blind, double-
dummy, parallel group study, conducted in 178
centres in 18 countries. Following a 2-week run-in
period, patients were randomised to receive either
SFC or FBC for 24 weeks. Patients attended study
visits at weeks 4, 8, 16 and 24 of the treatment
period and a post-study safety assessment was
performed by telephone, approximately 7 days
after completion or withdrawal. The study protocol
was approved by a national, regional or investiga-
tional centre scientific ethics committee or institu-
tional review board, and was conducted in
accordance with International Conference on Har-
monization Good Clinical Practice (ICH GCP) and
the Declaration of Helsinki (2000). Written in-
formed consent was obtained from each patient
prior to study enrolment.
Study population
Those eligible were male or female outpatients
aged 18 years or over, with a documented clinical
history of asthma of at least 6 months and who had
been receiving 1000–2000 mg/day of beclometha-
sone dipropionate or equivalent. Combination
therapy, if used, was discontinued and replaced
with ICS alone, at least 4 weeks prior to study start
(screening visit). At the screening visit, patients
were required to demonstrate a reversible increase
in forced expiratory volume in 1 s (FEV1) of 12% or
more, 15min after inhaling salbutamol 200–400 mg.
For entry to the randomised treatment period
(baseline), patients were required to demonstrate
a reversible increase in FEV1 of at least 12% (and
X200mL), 15min after inhaling salbutamol
200–400 mg, and an asthma symptom score (day
and night combined) of at least 2 (two or more
episodes of symptoms during the day/night) on at
least 4 of the last 7 evaluable days of the run-in
period. Patients were excluded from the study if
they had: suffered an upper or lower respiratory
tract infection or an acute asthma exacerbation
(requiring emergency treatment or hospitalisation)
within 4 weeks of Visit 1; used oral corticosteroids
within 4 weeks or depot steroids within 12 weeks of
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predicted value; or a smoking history of X10 pack
years.Treatment
Blinded study medication was packed and supplied
by GlaxoSmithKline (GSK). All treatment packs
contained both Diskus/Accuhaler and Turbuhaler
devices (either active Diskus/Accuhaler+placebo
Turbuhaler, or active Turbuhaler+placebo Diskus/
Accuhaler) and looked identical. The double-
dummy design ensured that both the patients and
the investigators remained blind to the active
medication being received. Patients were assigned
to study treatment in accordance with the rando-
misation schedule from the Interactive Voice
Recognition System, which was part of the GSK
System for the Central Allocation of Medication.
During the run-in period, patients continued on
their current ICS plus salbutamol as required. At
Visit 2, eligible patients were randomly assigned to
one of the following treatment groups for 24
weeks: SFC Diskus/Accuhaler 50/250 mg one inhalation
bid and placebo Turbuhaler two inhalations bid; placebo Diskus/Accuhaler one inhalation bid and
FBC Turbuhaler 6/200 mg two inhalations bid.
The doses of SFC and FBC given were those
recommended for this patient population with
persistent asthma, and patients were instructed
to use the Diskus/Accuhaler followed by the
Turbuhaler, both within 2min of each other, in that
order.Table 1 Exacerbation definitions.
Severity Definition
Mild  Morning PEF420% below baseline (mea
 More than 3 additional reliever occasio
consecutive days, or
 Awakening at night due to asthma for
Moderate Deterioration in asthma requiring treatm
days. This may be either:
 Morning PEF430% below baseline (mea
 A clinical deterioration assessed by th
treatment
Severe  Deterioration in asthma requiring hosp
PEF ¼ peak expiratory flow.Rate of exacerbations
The primary endpoint was the number of all asthma
exacerbations experienced by the patient ex-
pressed as a rate over the 24-week treatment
period. The severity of exacerbations was also
recorded. Exacerbations were assessed by the
physician at each scheduled visit by reviewing the
daily record card (DRC) on which patients were
asked to record information about their condition,
as well as by asking specific questions about
adverse events (AEs). Exacerbation definitions are
shown in Table 1.Lung function
Morning and evening PEF were recorded on the
DRC, prior to the use of rescue or study medication.
FEV1 was measured at each clinic visit and patients
were requested not to use short-acting bronchodi-
lators for at least 6 h prior to the measurement
being recorded.Asthma symptoms and rescue medication use
Patients recorded their level of symptoms on the
DRC each morning and evening, prior to the use of
rescue or study medication. Daytime scores were
based on a scale from 0 (no symptoms) to 5
(symptoms so severe that the patient could not go
to work or perform normal daily activities), and
night-time scores were based on a scale from 0 (no
symptoms) to 4 (symptoms so severe that the
patient was unable to sleep). The amount of rescue
medication used in the previous 12 h was also
recorded each morning and evening.n of last 7 days of run-in) forX2 consecutive days, or
ns/24-h period with respect to baseline for X2
X2 consecutive nights
ent with oral prednisolone 40–60mg per day for 7–10
n of last 7 days of run-in) forX2 consecutive days, or
e investigating physician as requiring oral steroid
ital admission
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A patient’s weekly asthma control status was
derived based on a composite measure. A week of
‘well-controlled’ asthma was defined as meeting
the following criteria, assessed each week over 7
consecutive days: Two or more of the following three criteria:
J a symptom score of 41 or no more than 2
days,
J no more than 2 days of rescue salbutamol use,
up to a maximum of 4 occasions per week,
J X80% predicted morning PEF every day. And all of the following criteria:
J no night-time awakenings due to asthma,
J no exacerbations,
J no emergency visits,
J no treatment-related AEs enforcing a change
in asthma therapy.Safety
The incidence and type of AEs were recorded
throughout the study. An AE was defined as any
untoward medical occurrence irrespective of caus-
ality. Oropharyngeal examinations were conducted
at each visit.Statistical analyses
The total sample size was determined on the basis
of anticipated differences between treatments in
average asthma exacerbation rate over a 24-week
treatment period. Based on data from two previous
studies,11,12 the average exacerbation rate for FBC
Turbuhaler is estimated to be one per patient per 6
months. To detect a difference of 20% in the
relative risk of exacerbations between SFC and
FBC, at a two-sided a ¼ 0:05 significance level with
90% power using the Normal approximation to the
Poisson regression techniques, 525 patients per
group were required.
Analysis of the primary and secondary efficacy
measures was based on the intent-to-treat (ITT)
population. The primary efficacy endpoint, rate of
exacerbations over the 24-week treatment period,
was analysed using a maximum-likelihood based
analysis assuming the Poisson distribution, with
time on treatment as an offset variable. The model
included adjustments for the effects of gender,
country grouping and age. A time effect was noted
following the initial analysis, therefore, further
analyses were conducted to investigate annualised
exacerbation rates over time. The number ofexacerbations in each interval (weeks 1–8, weeks
9–16 and weeks 17–24) was counted. Last observa-
tion carried forward (LOCF) was used to account for
missing data due to early withdrawal from the
study. The analysis of these data was performed
using Generalised Estimating Equation (GEE) meth-
odology adjusting for the main effects used in the
primary analysis, as well as time interval. The
number and severity of exacerbations were ana-
lysed using logistic (proportional odds) regression.
A separate analysis of the rate of moderate/severe
exacerbations was also performed following the
observation of a numerical imbalance in the
numbers of these exacerbations (Table 2). All
exacerbation-based analyses were repeated using
exacerbation data as strictly defined per protocol,
to present a more objective analysis of the data.
Lung function endpoints (FEV1 and PEF) and
symptom scores were analysed using analysis of
covariance (ANCOVA) adjusting for baseline, coun-
try, gender, age and treatment. The proportion of
patients achieving ‘well-controlled’ asthma was
assessed using a two-sided Fisher’s exact test. Safety
measures were presented as summary statistics.Results
Patients
A total of 1769 patients were screened for this
study, of which 1397 were randomised to treat-
ment: 697 to the SFC group and 700 to the FBC
group (Fig. 1). Six patients were subsequently
excluded due to a lack of adherence to ICH GCP
and therefore the final ITT population comprised
1391 patients: 694 in the SFC group and 697 in the
FBC group. After randomisation, 133 patients (10%)
were withdrawn: 71 (10%) from the SFC group and
62 (9%) from the FBC group. Baseline character-
istics, including lung function and previous asthma
medications, were well matched between the two
groups (Table 3). Patients were recruited from 178
centres in 18 countries. Several centres contribu-
ted 6 or less patients to the study, therefore
country grouping was used where appropriate. In
all efficacy analyses and tests of treatment inter-
actions, country grouping was not significant. This
would indicate that the results are valid in several
countries.
Exacerbation rates
For the primary endpoint, the adjusted mean rate
of all exacerbations over 24 weeks, as recorded by
ARTICLE IN PRESS
Table 2 Summary of exacerbations.
SFC 50/250 mg
(n ¼ 694)
FBC 6/200 mg
(n ¼ 697)
Mean rate over 24 weeks (Poisson model) 2.69 2.79
Treatment comparison
Ratio 0.96
95% CL 0.84, 1.10
P-value 0.571
Severity of exacerbations, n (%) patients
No exacerbations 258 (37) 246 (35)
Mild 369 (53) 371 (53)
Moderate/severe 67 (10) 80 (11)
Treatment comparison of moderate/severe exacerbationsy
Weeks 1–24: Adjusted mean rate/year 0.155 0.223
Ratio 0.70
95% CL 0.48, 1.01
P-value 0.059
Weeks 1–8: Adjusted mean rate/year 0.227 0.224
Ratio 1.01
95% CL 0.61, 1.67
P-value 0.96
Weeks 9–16: Adjusted mean rate/year 0.157 0.202
Ratio 0.78
95% CL 0.45, 1.35
P-value 0.371
Weeks 17–24: Adjusted mean rate/year 0.105 0.244
Ratio 0.43
95% CL 0.23, 0.79
P-value 0.006
SFC ¼ salmeterol/fluticasone propionate combination; FBC ¼ formoterol/budesonide combination.
Maximium severity of exacerbation experienced by patients.
yAs defined per protocol (PP), adjusting for time interval.
R. Dahl et al.1156the investigators, was similar in both treatment
groups (2.69 for SFC and 2.79 for FBC) (Table 2).
The majority of exacerbations were mild. Further
analysis of all exacerbations adjusting for time
interval, revealed a significant effect of time, such
that the rate of all exacerbations across both
treatment groups showed a 30% reduction in weeks
9–16 (95% CI 24–36%; Po0:001) and a 36% reduction
in weeks 17–24 (95% CI 30–42%; Po0:001) com-
pared with weeks 1–8. From approximately 8 weeks
of treatment, the cumulative number of exacerba-
tions, defined as per protocol (PP), was slightly
higher in the FBC group compared with the SFC
group, and this difference increased as time
progressed (Fig. 2a). However, there was no
statistically significant difference between the
groups.
Although there was no statistically significant
difference between treatments in terms of the
severity of exacerbations, a numerical imbalancebetween the groups in the number of moderate/
severe exacerbations (67 for the SFC group vs. 80
for the FBC group) was observed. Further analysis
showed that, adjusting for time, there was a 30%
reduction (95% CI 0–49%, 52% reduction (SFC) vs. 1%
increase (FBC); P ¼ 0:059) in the incidence of
moderate/severe exacerbations between treat-
ment groups with a treatment by-interval effect
overall approaching statistical significance
(P ¼ 0:055), indicating that there was a difference
between treatments over time. A cumulative plot
of the number of moderate/severe exacerbations
by study day in each treatment group is shown in
Fig. 2b. The treatment lines start to diverge after
about 3 months of treatment and the difference
between the groups increased with time. The
difference between the treatment groups was
statistically significant at weeks 17–24, where the
SFC group showed a 57% (0.105 vs. 0.244, SFC and
FBC, respectively, P ¼ 0:006) reduction in the rate
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1769 patients recruited
1397 patients randomised
to treatment
Data from one site
excluded from ITT
population (n=6)
ITT population = 1391 patients
694 patients
SFC
697 patients
FBC
623 patients completed 635  patients completed
372 patients withdrawn
n=282 did not fulfil e/c
n=8 adverse event
n=9 protocol violation
n=35 consent w/d
n=15 lost to follow-up
n=23 other
71 patients w/d
n=4 did not fulfil e/c
n=5 lack of efficacy
n=11 consent w/d
n=13 adverse event
n=13 protocol violation
n=16 lost to follow-up
n=9 other
62 patients w/d
n=2 did not fulfil e/c
n=2 lack of efficacy
n=10 adverse event
n=12 protocol violation
n=13 lost to follow-up
n=15 consent w/d
n=8 other
Figure 1 Patient flow. SFC ¼ salmeterol/fluticasone propionate combination; FBC ¼ formoterol/budesonide combina-
tion; e/c ¼ entry criteria; w/d ¼ withdrawn.
Primary results of the EXCEL study 1157of moderate/severe exacerbations compared with
the FBC group (Table 2 and Fig. 3).Lung function, asthma symptoms and rescue
medication use
Both treatment groups showed a steady increase in
mean morning PEF and mean FEV1 during the
treatment period (Table 4). Similar results were
shown for mean evening PEF and mean percent
predicted morning and evening PEF. Over weeks
1–24, mean7SD daytime symptom scores decreased
from 1.870.75 to 0.870.79 in the SFC group andfrom 1.870.73 to 0.870.78 in the FBC group
(treatment difference of 0.03; 95% CL 0.04, 0.10;
P ¼ 0:425). A large increase in the mean percen-
tage of symptom-free days/nights and days when
no rescue medication was used was also seen in
both groups (Table 4). There was no statistically
significant difference between treatments for
these parameters.‘Well-controlled’ asthma
The proportion of patients who achieved a week of
‘well-controlled’ asthma at any point during the
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Table 3 Demographic and baseline characteristics.
Characteristic SFC 50/250 mg (n ¼ 694) FBC 6/200 mg (n ¼ 697)
Age, mean years (range) 45.6 (18–91) 47.1 (18–82)
Sex, n (%)
Female 387 (56) 409 (59)
Male 307 (44) 288 (41)
Duration of asthma, n (%)
X6 months to o1 year 31 (4) 31 (4)
X1 year to o5 years 147 (21) 128 (18)
X5 years to o10 years 125 (18) 146 (21)
X10 years to o15 years 97 (14) 108 (15)
X15 years to o20 years 77 (11) 80 (11)
X20 years to o25 years 72 (10) 60 (9)
X25 years 145 (21) 144 (21)
No. of exacerbations in the last year, mean7SD
Requiring antibiotics/ICS 0.671.0 0.671.1
Requiring hospitalisation 0.170.3 0.170.3
Baseline symptoms, mean7SD
% symptom-free days 8.2716.98 7.3716.32
% symptom-free nights 31.5735.77 35737.64
PEFam
 (L/min), mean7SD 357.67112.45 348.47111.47
FEV1 (L) (n), mean7SD 2.570.85 2.470.85
% predicted FEV1, mean7SD 78.7717.86 78.5718.20
Reversibilityy at screening (n) 358 372
Mean7SD (%) 21.4713.37 22.3716.79
Reversibility at baseline (n) 90 104
Mean7SD (%) 19.6710.83 24.0714.78
PEFam ¼ morning peak expiratory flow; FEV1 ¼ forced expiratory volume in 1 s; SFC ¼ salmeterol/fluticasone propionate
combination; FBC ¼ formoterol/budesonide combination; ICS ¼ inhaled corticosteroid; SD ¼ standard deviation.
Mean over last 7 days of the run-in period.
yNot required to be measured if documented in last 2 years.
R. Dahl et al.1158treatment period was the same in both treatment
groups (SFC: 483 [70%]; FBC: 486 [70%]). Over
weeks 1–24, the mean number of weeks with ‘well-
controlled’ asthma was slightly higher in the SFC
group compared with the FBC group (10.279.2
weeks vs. 9.679.1 weeks) but this difference was
not statistically significant (P ¼ 0:391).Safety measures
Overall, both treatments were shown to be safe
and well tolerated. The incidence and type of AEs
were similar in both treatment groups and not
unexpected in patients with moderate-to-severe
asthma. The proportion of patients with at least
one AE that started during treatment was 384 (55%)
in the SFC group and 377 (54%) in the FBC group.The incidence of drug-related AEs was o10% in
both groups, the most commonly reported drug-
related AEs were: hoarseness/dysphonia (SFC: 13/
697 [2%]; FBC: 13/700 [2%]), candidiasis of mouth/
throat (SFC: 12/697 [2%]; FBC: 7/700 [1%]) and
headaches (SFC: 9/697 [1%]; FBC: 12/700 [2%]). No
deaths occurred in the study and only a small
proportion of patients reported serious AEs (SAEs).
Only one SAE was considered to be related to the
study drug: a severe hoarseness/dysphonia in a
patient in the FBC group. The incidence of oral
candidiasis was low in each treatment group and
none of the occurrences reported were serious.
Oral swabs were collected from 14 patients (2%) in
each treatment group due to clinical evidence of
candidiasis. Of these, 8 patients (1%) in the SFC
group and 7 patients (1%) in the FBC group had a
positive swab result.
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Figure 2 (a) Cumulative plot by study day of all exacerbations (intent-to-treat [ITT] population). (b) Cumulative plot
by study day of moderate/severe exacerbations.
Primary results of the EXCEL study 1159Discussion
The primary objective of the EXCEL study was to
compare the efficacy of SFC 500/250 mg one
inhalation bid with FBC 6/200 mg two inhalations
bid in preventing the occurrence of asthma
exacerbations in adults with persistent asthma. It
is one of the first studies to directly compare
the two LABA/ICS combination products, SFC and
FBC, in this population of persistent asthmatics
over a 6-month treatment period. Overall the
study found both treatments to be effective in
reducing the rate of exacerbations over 6 months
(primary endpoint) and to be equally safe and well
tolerated.It was assumed that the rate of exacerbations
would remain constant throughout the 24-week
treatment period. However, because there was a
clear improvement with time on regular treatment
in other endpoints, such as PEF and rescue
medication use, a similar treatment effect for the
rate of exacerbations was considered possible.
Further analyses were carried out to investigate
the effect of regular, stable dose treatment on
exacerbation rates over time. The interval of
8-week periods used to analyse the time effect of
treatment on exacerbation rate was consistent
with time intervals used in another study.13 As the
definitions of exacerbations had been clearly stated
in the study protocol, the analyses were also
ARTICLE IN PRESS
Figure 3 Adjusted moderate/severe exacerbation rates, as defined per protocol (PP), by study interval. Overall
treatment difference: P ¼ 0.059. *Treatment difference in Interval 3: P ¼ 0.006.
Table 4 Lung function and patient-rated data.
Parameter SFC 50/250 mg
(n ¼ 694)
FBC 6/200 mg
(n ¼ 697)
PEFam (L/min)
Baseline mean7SD 357.57112.8 348.37111.6
Adjusted mean change7SE 41.871.7 41.471.8
PEFam, % predicted
Baseline mean7SD 78.9719.3 78.3719.4
Adjusted mean change7SD 9.270.4 9.070.4
FEV1 (L)
Baseline mean7SD 2.4370.8 2.4070.9
Adjusted mean change7SE 0.2970.02 0.2770.02
% symptom-free days
Baseline median (range) 0 (0–100) 0 (0–100)
Weeks 1–24 median (range) 63 (0–100) 60 (0–100)
% symptom-free nights
Baseline median (range) 14 (0–100) 25 (0–100)
Weeks 1–24 median (range) 85 (0–100) 86 (0–100)
% rescue-free days
Baseline median (range) 0 (0–100) 0 (0–100)
Weeks 1–24 median (range) 82 (0–100) 81 (0–100)
PEFam ¼ morning peak expiratory flow; FEV1 ¼ forced expiratory volume in 1 s; SFC ¼ salmeterol/fluticasone propionate
combination; FBC ¼ formoterol/budesonide combination; SD ¼ standard deviation; SE ¼ standard error.
R. Dahl et al.1160performed using exacerbation as strictly defined by
the protocol in order to more objectively analyse
the data. The results from both sets of data
(investigator-defined and protocol-defined exacer-
bations) showed a significant reduction in the rate
of exacerbations over time in both treatment
groups starting from approximately 12 weeks oftreatment and continuing to plateau off over the
remaining 12 weeks of the study.
A numerical difference in the number of patients
experiencing moderate/severe exacerbations (67
for the SFC group vs. 80 for the FBC group) over the
6-month treatment period was observed. Further
analyses showed a 30% lower annualised rate of
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Primary results of the EXCEL study 1161moderate/severe exacerbations for SFC than with
FBC. This effect increased with time and became
most prominent in the last 8 weeks of treatment,
where there was a significant 57% difference in the
moderate/severe exacerbation rate in favour of
SFC (P ¼ 0:006). These findings are important for
the clinician given the extensive morbidity and
cost-implications associated with moderate/severe
asthma exacerbations.14
Both treatment groups showed a similar and
clinically relevant improvement in lung function
(PEF and FEV1) from baseline to the end of
treatment. Similar improvements in asthma symp-
toms and use of rescue medication were also shown
in both treatment groups. These findings confirm,
as with the Evaluation of Different Inhaled Combi-
nation Therapies (EDICT) study,12 that regular,
stable dose treatment at an appropriate ICS dose
in the form of combination therapy can improve
lung function and asthma symptoms even when
patients are already receiving moderate-to-high
doses of ICS. This phenomenon is well known and
other studies have also shown the improvement
over time with regular ICS therapy.13 Regular
treatment with inhaled budesonide over 9 months
suppressed activation markers of eosinophils and
neutrophils, and a higher dose of budesonide gave a
superior effect, reduced exacerbations and pro-
gressively reduced bronchial hyperresponsiveness
to inhaled histamine, supporting a time effect of
ICS and a superior outcome with regular treat-
ment.15,16 The significant difference in moderate/
severe exacerbation rates between SFC and FBC
over time seen in this study may, in part, be due
to differences in the molecular actions of the
two treatments in this population of asthmatics
and possibly also to differences in drug delivery
between the Diskus/Accuhaler and the Turbuhaler.
This was a fully blinded, double-dummy study
and compliance with both inhaler devices was
high so preference of the Diskus over the Turbu-
haler by patients is unlikely to explain the
difference in clinical outcomes over time in this
study. Further research may help to explain
the mechanisms behind the observations in the
EXCEL study.
In conclusion, the data from this study showed
that regular, twice-daily treatment with SFC and
FBC over 6 months significantly improved asthma
symptoms and lung function in the study population
of adults with persistent asthma. The rate of
exacerbations was also reduced over time on both
treatments; however, SFC was found to be sig-
nificantly superior to FBC in reducing the rate of
moderate/severe exacerbations with regular,
stable dose treatment.Acknowledgements
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